Anova has designed a new approach to conducting clinical trials. Our AnovaOS™ platform shaves years off the time to bring new investigational products to market, reduces product development cost, improves patient access to investigational treatments and facilitates a move to a patient-focused development approach grounded in precision medicine.
Our AnovaOS™ platform brings the worlds research environment to the doorstep of every investigator and sponsor. With 130k active studies, 15k sponsors, 15k investigational products, 40k research sites and over 100k investigators, we are transforming the clinical research industry by accelerating development and helping patients access research wherever they receive care.
Applying transformative technology to improve data quality, decrease cost and accelerate clinical development.
Disrupting and transforming the traditional clinical development approach.
Aligning the interests of all stakeholders to form a first-in-kind healthcare focused clinical development network.
Applying fact-based decision making to drive a continuous learning system.
Chris is a highly-experienced leader in the drug development community where he has offered start-up, regulatory, project management, and operational experience within the healthcare industry. Chris previously co-founded, grew and sold two healthcare companies including a multi-site medical oncology and research company which specialized in the conduct of Phase I and early Phase II clinical trials and the care of patients with advanced cancer, and a site management organization focused on the conduct of cancer clinical trials.
These companies had pivotal roles in the FDA approval of important treatments, including Abraxane, Avastin, Sutent, Nivolumab, and Palbociclib. Chris has been a long-standing advocate of the need for positive transformational change in the clinical research industry.
Martin is a highly-experienced leader with deep service and market development experience in healthcare, technology and biotechnology sectors.
He has built and led service and technology companies supporting care coordination, next-generation sequencing and clinical research operations with a proven P&L track record for both first-to-market and mature solutions.
He has proven success in high-growth industries, building strong solutions, clinical, operations, technical and sales teams.
When he is not spending his time trying to figure out ‘if not now, then when…,’ he can be found on a bike, or watching his two sons beat him at all games that were ever sacred to him.
Dr. Fred Ma brings 30 years of global regulatory success, groundbreaking clinical innovation, and executive leadership. He has held leadership positions at Jonhson and Johnson, Merck and GE Healthcare. His expertise in oncology, neuroscience, immunology, and cell and gene therapies has been instrumental in advancing more than 1,000 clinical trials and achieving numerous regulatory approvals worldwide. Beyond research and development, Dr. Ma has driven exceptional return on investment (ROI) through his leadership in marketing, sales, and operations, not only in the U.S. but also across Europe, South America, and the Asia-Pacific region.
Rhonda Rosen, appointed as Chief Finance Officer, brings 30 years senior finance executive leadership experience that spans all areas of finance, banking and administration. She has executive experience in contract research organization (CRO) and life-science companies, including board and investor communications, M&A, public and private financing transactions, and initial public offerings. Her has a proven track record leading the growth and dramatic improvement of multiple early stage, mid-sized and PE/ VC backed companies, including closing over 60 M&A transactions.
Dr. Mukherjee is an Associate Professor of Medicine at Columbia University and a Staff Physician at Columbia University Medical Center. Dr. Mukherjee is the author of “The Emperor of All Maladies: A Biography of Cancer,” winner of the 2011 Pulitzer Prize in general nonfiction, “The Laws of Medicine” and “The Gene: An Intimate History.” Dr. Mukherjee’s laboratory seeks to understand the biology of blood development, with a special interest in malignant and premalignant blood diseases and a goal of developing novel therapeutic strategies. Dr. Mukherjee trained as a hematologist and oncologist at the Dana-Farber Cancer Institute of Harvard Medical School and was on the staff at the Massachusetts General Hospital. Dr. Mukherjee obtained a DPhil in immunology from Oxford as a Rhodes Scholar and an MD from Harvard Medical School.
Dr. Palmer is an experienced medical oncologist who has led the way in the development and use of genomic medicine. He most recently was the Chief Medical Officer at Tempus, Inc., a leader in the field of genomics and real world evidence. He has been in the biotech industry for twenty years and has held leadership roles at Amgen, Genomic Health, Foundation Medicine, and NantHealth. He has been instrumental in the development of Neulasta, the Oncotype DX Breast Assay, the Foundation One solid tumor multigene assay, and the Tempus xT and xF platforms.
Before his roles in industry, Dr. Palmer served as a medical oncologist in both academia and in the community setting. Dr. Palmer was director of the Medical Breast Service at the University of California, Davis, Cancer Center and Chief of Medical Oncology at the Mercy Health System, Sacramento, California before starting his career in industry.
Dr. Palmer is a magna cum laude graduate of Yale University and a graduate of the Stanford University School of Medicine. He did his internal medicine training at the Boston City Hospital and his oncology fellowship at the Massachusetts General Hospital He has a Masters in Business Administration (MBA) from the University of California, Davis, and a Masters in Public Health (MPH) from U.C.L.A. As well, Dr. Palmer holds a J.D. degree and is admitted as an attorney to the State Bar of California.
Névine Zariffa is a highly accomplished thought leader in the field of data science with extensive experience across all phases of drug development. She is a recognized industry expert in drug development with a 25-year career at GlaxoSmithKline (GSK) and AstraZeneca (AZ). Névine led the Enterprise Data & Analytics initiative at AZ, and she has been a key contributor to development strategies and numerous health authority interactions for over 200 drug projects across oncology, cardiovascular, metabolic, respiratory, inflammation, urology and renal diseases.
Névine is currently a strategic consultant dedicated to advancing healthcare. She is a consultant to the FDA, Office of the Principal Deputy Commissioner, on the application of real-world evidence to COVID19.
Névine was a member of the Clinical Data Interchange Standards Consortium (CDISC) Board of Directors from 2014-2019. She was a reviewer for The Lancet and an author/coauthor of over 25 peer reviewed publications in biostatistics/medical journals. She is a frequent speaker and panelist at scientific conferences.
She has a master’s degree in Statistics from Waterloo University in Ontario, Canada and a Bachelor of Science degree in Mathematics from McGill University in Montreal, Quebec. She is fluent in English and French and a dual US/Canadian citizen.
Dr. Pluard is medical director at Saint Luke’s Cancer Institute and the Paul Koontz Endowed Chair of Breast Disease at the University of Missouri – KC School of Medicine. Under his leadership, Saint Luke’s has launched two new signature cancer centers.
In 2017, Dr. Pluard led the creation of Saint Luke’s Center for Precision Oncology, that brings together experts in clinical oncology, tumor genomics, and computational biology. This unique multidisciplinary team has the expertise to identify the exact genomic alteration causing a patient’s tumor, and find the best possible treatment—even if it has never been used on that kind of cancer before.
Prior to joining Saint Luke’s, Dr. Pluard served as associate professor of medicine at Washington University in Saint Louis, and clinical director of the breast oncology program at Siteman Cancer Center, a National Cancer Institute designated Comprehensive Cancer Center.
He has published extensively on new therapeutic approaches to breast cancer and the care of metastatic breast cancer patients.
“Anova and ERC crafted an ethical Right-to-Try program that has helped patients with brain tumors and generated survival data that has became integral to our regulatory submissions. When we secure marketing approval it will be, in part, due to our partnership with Anova.”
“OPN Healthcare is a specialty healthcare services company focused on cancer care, with over 1 million covered lives. Our partnership with Anova has been helped us to establish a robust clinical research program across our practices in southern California and improve access to promising new treatments for our patients. Within our first six months of operation we have recruited dozens of patients into clinical trials and the program is continuing to grow rapidly.”
“Anova’s deep regulatory and technical expertise has helped our company navigate conflicts that can (and do) arise with traditional CRO partners. Ethical research that complies with regulatory requirements is a foundation of our work. On multiple occasions, Anova has recommended a path that has been validated by regulators to be the best approach for our company and our products for patients with herpes and COVID-19.”
“The South Sound Care Foundation supports providers across the South Sound region access targeted therapies for patients with cancer. Anova has been instrumental in helping our team establish a robust compassionate use program and providing the technology required to deliver seamless and compliant compassionate use for our providers.”
“Anova’s forward-thinking approach to Expanded Access has brought Celularity investigational products to cancer and COVID-19 patients in need while generating data that has directly impacted our traditional development efforts.”
